Loading...
NPI 1912901877 · Peoria, IL · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Min-kyu Han is a ophthalmology physician provider located in Peoria, Illinois. This profile covers 21 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Min-kyu Han |
| Address | 8921 N Wood Sage Rd |
| City | Peoria |
| State | IL |
| ZIP | 61615 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 9, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.9M |
| Medicaid | $547.6K |
Payer mix and scale: This provider is Medicare-dominant by revenue, with total Medicare revenue of $4.9M versus total Medicaid revenue of $547.6K, indicating Medicare is roughly an order of magnitude larger as the revenue source for this practice. Both payers are active on file, but the practice’s financial footprint is concentrated in Medicare.
Medicare revenue concentration: The provider’s Medicare billing is highly concentrated — the precomputed top 3 Medicare codes account for 86.6% of this provider's total Medicare revenue. Those top drivers are J2777 ($2.3M, 47.4%), J0178 ($1.6M, 33.2%), and 67028 ($292.3K, 5.9%), showing that two injectable drug codes dominate Medicare receipts.
Medicaid revenue concentration: Medicaid revenue is similarly concentrated, with the precomputed top 3 Medicaid codes making up 81.4% of total Medicaid revenue. The Medicaid mix is led by 67028 ($284.7K, 52.1%), followed by J0178 ($96.7K, 17.7%) and J2777 ($63.4K, 11.6%), indicating intravitreal injections are the core Medicaid service line for this provider as well.
Service-line implications: The code mix (dominant J2777 and J0178 injectables plus high-volume procedural codes like 67028 and diagnostic imaging 92134) points to a retina-focused ophthalmology practice centered on intravitreal drug administration and retinal imaging. High counts for injection codes (e.g., J2777: 80.5K claims Medicare; J0178: 2.4K claims Medicare) paired with 92134 (4K Medicare claims) suggest routine, high-frequency injection visits supported by retinal imaging and E/M visits.
Medicare competitive standing and outlier signals: The provider is a national outlier for faricimab (J2777) — J2777 is ranked #30 of 2039 providers nationally (99th percentile; extreme outlier) and generates $2.3M (47.4% of Medicare revenue). The practice is also an extreme outlier on J7312 (rank #8 of 492 nationally, 99th percentile; extreme outlier) and shows notably above-typical volume on 67028 (rank #89 of 4255 nationally, 98th percentile). These ranks indicate the provider is a major national contributor to faricimab and other intravitreal therapy billing.
Medicaid competitive standing: Within Illinois Medicaid, the provider’s 67028 volume is substantial but not uniquely dominant — 67028 ranks #24 of 120 in-state (81th percentile; typical, unremarkable volume) even though it represents $284.7K (52.1% of Medicaid revenue). For faricimab (J2777) the provider ranks #3 of 5 in-state (50th percentile), reflecting that faricimab use in Medicaid is concentrated in very few in-state providers and this practice is one of them, despite modest absolute Medicaid dollars for that code.
Operational and revenue implications: Large Medicare receipts tied to high-cost injectable drugs (J2777 $2.3M and J0178 $1.6M) imply a business model with significant drug procurement, billing, and administration throughput. These drug-driven revenue streams likely dominate margins and operational planning (inventory, infusion/ injection capacity, and payer contract sensitivity) relative to office-based E/M and testing codes, which contribute smaller shares (for example, 92134 contributes $120.2K to Medicare revenue).
Tenure and practice stability: The NPI has been enumerated since 2005-06-09 (~21 years ago), indicating a long-established practice presence in PEORIA, IL. Combined with consistently high-volume Medicare injectable billing and stable Medicaid procedures, the data point to a mature clinical operation with established clinical workflows for retina care.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 80,520 | $30 | $2.3M |
| J0178 | Injection, aflibercept, 1 mg | 2,380 | $690 | $1.6M |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,110 | $90 | $292.3K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 780 | $160 | $123.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 4,010 | $30 | $120.2K |
| J0179 | Injection, brolucizumab-dbll, 1 mg | 450 | $250 | $111.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,100 | $90 | $103.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 640 | $80 | $52.2K |
| J9035 | Injection, bevacizumab, 10 mg | 880 | $50 | $44.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 460 | $60 | $28.1K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 14 | 140 | 700 | $690 | $688.4K |
| J2777 | 1 | 90 | 9,180 | $30 | $451K |
| J0179 | 1 | 10 | 450 | $250 | $111.2K |
| 67028 | 1 | 190 | 400 | $90 | $64.4K |
| J7312 | 1 | 30 | 240 | $160 | $45.1K |
| 92014 | 192 | 1,420 | 130 | $80 | $24.7K |
| J9035 | 12 | 130 | 140 | $60 | $24.6K |
| 67210 | 14 | 20 | 30 | $410 | $22K |
| 67042 | 22 | 50 | 20 | $870 | $21.8K |
| 67108 | 13 | 30 | 20 | $880 | $17.6K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,060 | $140 | $284.7K |
| J0178 | Injection, aflibercept, 1 mg | 120 | $830 | $96.7K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 70 | $880 | $63.4K |
| J9035 | Injection, bevacizumab, 10 mg | 1,290 | $50 | $59.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,550 | $10 | $30.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 340 | $30 | $8.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 140 | $20 | $2.8K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 10 | $20 | $320 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 28 | 50 | 200 | $1,100 | $391.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 24 | 120 | 540 | $160 | $166.3K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 3 | 10 | 70 | $920 | $142.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 699 | 1,230 | 450 | $40 | $54.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 9,442 | 14,680 | 300 | $50 | $48.7K |
| J9035 | Injection, bevacizumab, 10 mg | 15 | 80 | 290 | $60 | $43.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 45 | 250 | 510 | $20 | $20.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 611 | 670 | 230 | $30 | $16K |
Other providers in the same ZIP code as Min-kyu Han, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| J A K Enterprises Inc | IL | Eyewear Supplier | $0 | $13.9M |
| Saint Francis Medical Center | IL | Home Health Agency | $0 | $11.3M |
| Center For Health Ambulatory Surgery Center, LLC | IL | Ambulatory Surgical Clinic/Center | $2.8M | $0 |
| Michael Veeder | IL | Hematology & Oncology Physician | $2.4M | $153.7K |
| Paul Fishkin | IL | Hematology & Oncology Physician | $2.1M | $240.1K |
| Gregory Gerstner | IL | Hematology & Oncology Physician | $1.9M | $166.7K |
| Cristen Banks | IL | Nurse Practitioner | $2M | $17.5K |
| Madhuri Bajaj | IL | Hematology & Oncology Physician | $1.8M | $153.1K |
| Srinivas Jujjavarapu | IL | Hematology & Oncology Physician | $1.7M | $216.6K |
| Venkata Damarla | IL | Hematology & Oncology Physician | $1.7M | $106.4K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.